Breast Cancer
Reports summarize breast cancer study results from INSERM
Published in Cancer Weekly, November 10th, 2009
According to recent research published in the American Journal of Clinical Oncology - Cancer Clinical Trials, "In women with Human Epidermal growth Receptor 2 (HER2)-positive Metastatic breast cancer (MBC), Trastuzumab has become the standard of care but previous studies have raised doubts about its economic acceptability. We carried out the first cost-effectiveness study for Trastuzumab in MBC patients, in France, that is based on observed resource use and outcomes in clinical practice."
"We retrospectively analyzed 47 HER2-positive MBC patients in a before-and-after design study. Nineteen patients did not receive Trastuzumab (''before'' Trastuzumab introduction...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-11-10)
More Articles from Cancer Weekly
- Breast Cancer
New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors - Cancer Gene Therapy
Data on cancer gene therapy detailed by M. Grohmann and co-authors - Cancer Gene Therapy
New cancer gene therapy research from V. Mlakar and colleagues discussed - Cancer Gene Therapy
New cancer gene therapy study results from University of Texas described - Cancer Vaccines
New findings reported from V.T. Ho and co-authors describe advances in cancer vaccines - Cancer Vaccines
Researchers at University of Washington target cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
